Invention Grant
- Patent Title: Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
-
Application No.: US16099997Application Date: 2017-05-10
-
Publication No.: US11306124B2Publication Date: 2022-04-19
- Inventor: Philippe Karoyan
- Applicant: SORBONNE UNIVERSITE , Centre National de la Recherche Scientifique
- Applicant Address: FR Paris; FR Paris
- Assignee: SORBONNE UNIVERSITE,Centre National de la Recherche Scientifique
- Current Assignee: SORBONNE UNIVERSITE,Centre National de la Recherche Scientifique
- Current Assignee Address: FR Paris; FR Paris
- Agency: Christensen O'Connor Johnson Kindless PLLC
- Priority: EP16305543 20160510
- International Application: PCT/EP2017/061233 WO 20170510
- International Announcement: WO2017/194634 WO 20171116
- Main IPC: C07K7/50
- IPC: C07K7/50 ; C07K7/64 ; A61P37/06 ; A61P29/00 ; A61K38/00 ; C07K14/47 ; C07K14/705
Abstract:
The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.
Public/Granted literature
Information query
